These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 1973942

  • 1. Gepirone in the treatment of major depression.
    Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME, Reich LA.
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):77S-85S. PubMed ID: 1973942
    [Abstract] [Full Text] [Related]

  • 2. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 3. Gepirone as a 5-HT1A agonist in the treatment of major depression.
    Rausch JL, Ruegg R, Moeller FG.
    Psychopharmacol Bull; 1990 Aug; 26(2):169-71. PubMed ID: 1978370
    [Abstract] [Full Text] [Related]

  • 4. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.
    Robinson DS, Rickels K, Feighner J, Fabre LF, Gammans RE, Shrotriya RC, Alms DR, Andary JJ, Messina ME.
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):67S-76S. PubMed ID: 2198303
    [Abstract] [Full Text] [Related]

  • 5. Relapse prevention with gepirone ER in outpatients with major depression.
    Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J.
    J Clin Psychopharmacol; 2005 Feb; 25(1):79-84. PubMed ID: 15643103
    [Abstract] [Full Text] [Related]

  • 6. Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients.
    Rausch JL, Stahl SM, Hauger RL.
    Biol Psychiatry; 1990 Jul 01; 28(1):73-8. PubMed ID: 1973905
    [Abstract] [Full Text] [Related]

  • 7. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.
    Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K.
    J Clin Psychiatry; 2008 Apr 01; 69(4):571-7. PubMed ID: 18373383
    [Abstract] [Full Text] [Related]

  • 8. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, Gibertini M.
    J Clin Psychiatry; 2003 Mar 01; 64(3):243-9. PubMed ID: 12716264
    [Abstract] [Full Text] [Related]

  • 9. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial.
    Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C.
    J Clin Psychopharmacol; 1997 Aug 01; 17(4):272-7. PubMed ID: 9241006
    [Abstract] [Full Text] [Related]

  • 10. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement.
    McGrath PJ, Stewart JW, Quitkin FM, Wager S, Jenkins SW, Archibald DG, Stringfellow JC, Robinson DS.
    J Clin Psychopharmacol; 1994 Oct 01; 14(5):347-52. PubMed ID: 7806692
    [Abstract] [Full Text] [Related]

  • 11. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients.
    Wilcox CS, Ferguson JM, Dale JL, Heiser JF.
    Psychopharmacol Bull; 1996 Oct 01; 32(3):335-42. PubMed ID: 8961776
    [Abstract] [Full Text] [Related]

  • 12. Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression.
    Amsterdam JD.
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 May 01; 16(3):271-80. PubMed ID: 1350353
    [Abstract] [Full Text] [Related]

  • 13. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
    Feiger AD.
    Psychopharmacol Bull; 1996 May 01; 32(4):659-65. PubMed ID: 8993088
    [Abstract] [Full Text] [Related]

  • 14. Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis.
    Fabre LF, Smith LC, DeRogatis LR.
    J Sex Med; 2011 Sep 01; 8(9):2569-81. PubMed ID: 21707926
    [Abstract] [Full Text] [Related]

  • 15. Serotonergic anxiolytics and treatment of depression.
    Robinson DS, Alms DR, Shrotriya RC, Messina M, Wickramaratne P.
    Psychopathology; 1989 Sep 01; 22 Suppl 1():27-36. PubMed ID: 2657837
    [Abstract] [Full Text] [Related]

  • 16. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
    Amsterdam JD, Brunswick DJ, Gibertini M.
    J Psychiatr Res; 2004 Sep 01; 38(3):259-65. PubMed ID: 15003431
    [Abstract] [Full Text] [Related]

  • 17. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women.
    Fabre LF, Brown CS, Smith LC, Derogatis LR.
    J Sex Med; 2011 May 01; 8(5):1411-9. PubMed ID: 21324094
    [Abstract] [Full Text] [Related]

  • 18. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men.
    Fabre LF, Clayton AH, Smith LC, Goldstein I, Derogatis LR.
    J Sex Med; 2012 Mar 01; 9(3):821-9. PubMed ID: 22240272
    [Abstract] [Full Text] [Related]

  • 19. A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone.
    Robinson DS, Sitsen JM, Gibertini M.
    Clin Ther; 2003 Jun 01; 25(6):1618-33. PubMed ID: 12860488
    [Abstract] [Full Text] [Related]

  • 20. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone.
    Eison AS, Eison MS, Stanley M, Riblet LA.
    Pharmacol Biochem Behav; 1986 Mar 01; 24(3):701-7. PubMed ID: 2871564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.